Dr. Reddy’s Launches Oral semaglutide in India, Expands GLP-1 Diabetes Portfolio
Dr. Reddy’s Laboratories has announced the launch of Obeda® tablets, an oral semaglutide therapy for patients with diabetes in India. The launch marks another major step in the company’s expansion of its GLP-1 portfolio after recently introducing semaglutide injections in India and Canada.




















